Activation of the Zymogen to Urokinase-Type Plasminogen Activator Is Associated with Increased Interdomain Flexibility

被引:9
|
作者
Behrens, Manja A. [2 ,3 ]
Botkjaer, Kenneth A. [1 ,4 ]
Goswami, Sumit [5 ]
Oliveira, Cristiano L. P. [2 ,3 ]
Jensen, Jan K. [1 ,4 ]
Schar, Christine R. [1 ]
Declerck, Paul J. [5 ]
Peterson, Cynthia B. [6 ]
Andreasen, Peter A. [1 ,4 ]
Pedersen, Jan Skov [2 ,3 ]
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ, Dept Chem, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark
[4] Danish Chinese Ctr Proteases & Canc, Aarhus, Denmark
[5] Katholieke Univ Leuven, Dept Pharmaceut Sci, B-3000 Louvain, Belgium
[6] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA
基金
新加坡国家研究基金会;
关键词
small-angle X-ray scattering; serine protease; analytical ultracentrifugation; kringle; epidermal growth factor; PROTEIN UROKINASE; DOMAIN-STRUCTURE; STRUCTURAL BASIS; SCATTERING; SITE; MACROMOLECULES; INITIATION; RECEPTORS; MECHANISM; DYNAMICS;
D O I
10.1016/j.jmb.2011.05.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A key regulatory step for serine proteases of the trypsin clan is activation of the initially secreted zymogens, leading to an increase in activity by orders of magnitude. Zymogen activation occurs by cleavage of a single peptide bond near the N-terminus of the catalytic domain. Besides the catalytic domain, most serine proteases have N-terminal A-chains with independently folded domains. Little is known about how zymogen activation affects the interplay between domains. This question is investigated with urokinase-type plasminogen activator (uPA), which has an epidermal growth factor domain and a kringle domain, connected to the catalytic domain by a 15-residue linker. uPA has been implicated under several pathological conditions, and one possibility for pharmacological control is targeting the conversion of the zymogen pro-uPA to active uPA. Therefore, a small-angle X-ray scattering study of the conformations of pro-uPA and uPA in solution was performed. Structural models for the proteins were derived using available atomic-resolution structures for the various domains. Active uPA was found to be flexible with a random conformation of the amino-terminal fragment domain with respect to the serine protease domain. In contrast, pro-uPA was observed to be rigid, with the amino-terminal fragment domain in a fixed position with respect to the serine protease domain. Analytical ultracentrifugation analysis supported the observed difference between pro-uPA and uPA in overall shape and size seen with small-angle X-ray scattering. Upon association of either of two monoclonal Fab (fragment antigen-binding) fragments that are directed against the catalytic domain of, respectively, pro-uPA and uPA, rigid structures were formed. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:417 / 429
页数:13
相关论文
共 50 条
  • [1] Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid
    Akinci, Bans
    Terzi, Cem
    Sevindik, Gokmen
    Yuksel, Faize
    Tunc, Ulku Aybuke
    Tunali, Sunay
    Yesil, Sena
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 844 - 849
  • [2] Urokinase-type plasminogen activator
    Crippa, Massimo P.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (04): : 690 - 694
  • [3] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [4] Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis
    Lahtinen, Laura
    Lukasiuk, Katarzyna
    Pitkanen, Asla
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 24 (07) : 1935 - 1945
  • [5] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
    Ohba, K
    Miyata, Y
    Kanda, S
    Koga, S
    Hayashi, T
    Kanetake, H
    JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
  • [6] Targeting proteases in cancer: Discovery of a novel zymogen targeting inhibitor of urokinase-type plasminogen activator
    Botkjoer, K. A.
    Blouse, G. E.
    Deryugina, E. I.
    Byszuk, O.
    Jensen, J. M.
    Mortensen, K. K.
    Quigley, J. P.
    Andreasen, P. A.
    APMIS, 2008, 116 (05) : 414 - 414
  • [7] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [8] Nuclear translocation of urokinase-type plasminogen activator
    Stepanova, V.
    Kuo, A.
    Higazi, A.
    Yarovoi, S.
    Bdeir, K.
    Cines, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 228 - 228
  • [9] Plasma clearance of urokinase-type plasminogen activator
    van der Kaaden, ME
    Rijken, DC
    van Berkel, TJC
    Kuiper, J
    FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 (04): : 251 - 258
  • [10] Inhibition of urokinase-type and tissue-type plasminogen activator - Mediated plasminogen activation by doxycycline
    Hanemaaijer, R
    Visser, H
    vandenHoogen, CM
    Sorsa, T
    vanHinsbergh, VWM
    FIBRINOLYSIS, 1996, 10 : 109 - 111